IL6 and rheumatic disorder: Tocilizumab is considered a mainstay in the treatment of rheumatological disorders sustained by the activation of the IL-6/IL-6R pathway, and although its use is associated with an increase in cholesterol levels, it appears to have a safe CV profile [194] and to be protective against vascular diseases, as it improves endothelial function with a reduction in arterial stiffness [195].